Series B funding round for Capstan Therapeutics raising $180M in March 2024
Series B funding round for Capstan Therapeutics raising $180M in March 2024
| Investor | Firm Type | Partner |
|---|
| Private | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Public | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Private Equity | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Public | — | |
| Private | — | |
| Corporate Venture Capital | — | |
| Angel | Olivier Pomel | |
| Angel | Eli Lilly | |
| Angel | Vincent Brichard | |
| Angel | Ed Mathers | |
| Angel | Xavier Niel |
This company has completed 2 funding rounds. Current round is highlighted.
Total Raised
$280M
Top Valuation
-
Capstan Therapeutics raised $180M in a Series B round.
The round was announced on 03/01/24.
The round was led by Nandita Shangari.